Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like T*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2022 64764030020 Entyvio 300mg 20mL Vial 01/04/2022 436.60 7713.23 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000232 TerSera Therapeutics LLC 03/31/2022 70720012585 (New Labeler Code) XERMELO (telostristat ethyl), Oral Tablet, 250mg, 1 Case/84 Tablets 01/01/2022 370.52 7932.07 02/27/2031 Single Source Drug None 1 None 1 None 1 09/08/2020 Lexicon Pharmaceuticals, Inc 159000000 None " Lexicon received approximately $159M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer." 6559.00 5961.00 2017 5164.00 None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. This product's NDC description matches another product inside this manufacturers submissions, but the NDCs are different. This is due to the manufacturer acquiring the product and then changing the NDC to their labeler code in the past few months.
Rx0000232 TerSera Therapeutics LLC 03/31/2022 70720095036 ZOLADEX (goserelin implant), 3.6mg, 1 Syringe 01/01/2022 36.60 783.61 04/13/2022 Single Source Drug None 1 None 1 None 1 04/06/2018 AztraZeneca 320000000 None AstraZeneca received a $250m upfront payment for the rights of Zoladex, with double-digit quarterly sales-based payments being recieved on an ongoing basis. A further $70m was also in the sell should Zoladex meet a series of sales-related milestones 605.00 550.50 1989 265.63 None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000217 Teva Neuroscience, Inc. 03/31/2022 68546017260 AUSTEDO TABLETS 12MG 60 01/01/2022 485.37 6629.90 09/15/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2022 68546017060 AUSTEDO TABLETS 6MG 60 01/01/2022 323.60 4419.90 09/15/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2022 68546017160 AUSTEDO TABLETS 9MG 60 01/01/2022 364.10 4972.40 09/15/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2022 68546014256 AZILECT TABLET 0.5MG 30 01/01/2022 85.60 996.50 08/27/2027 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2022 68546022956 AZILECT TABLET1MG 30 01/01/2022 85.60 996.50 08/27/2027 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459051230 ACTIQ Lozenge 1200MCG 30 01/01/2022 537.60 6256.40 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459051630 ACTIQ Lozenge 1600MCG 30 01/01/2022 663.20 7718.10 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459050230 ACTIQ Lozenge 200MCG 30 01/01/2022 225.30 2621.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459050430 ACTIQ Lozenge 400MCG 30 01/01/2022 285.10 3318.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459050830 ACTIQ Lozenge 800MCG 30 01/01/2022 413.60 4813.20 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459050630 ACTIQ Lozenge 600MCG 30 01/01/2022 349.40 4066.40 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844011001 ADDERALL TABLET 10MG 100 01/01/2022 77.03 896.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844012001 ADDERALL TABLET 20MG 100 01/01/2022 77.03 896.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844013001 ADDERALL TABLET 30MG 100 01/01/2022 77.03 896.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844011201 ADDERALL TABLET12.5MG 100 01/01/2022 77.03 896.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844011501 ADDERALL TABLET15MG 100 01/01/2022 77.03 896.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844010501 ADDERALL TABLET5MG 100 01/01/2022 77.03 896.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844011701 ADDERALL TABLET7.5MG 100 01/01/2022 77.03 896.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459070060 AMRIX ORAL CAPSULE ER 15 MG 60 01/01/2022 260.70 3034.50 02/26/2025 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459070160 AMRIX ORAL CAPSULE ER 30 MG 60 01/01/2022 260.70 3034.50 02/26/2025 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459054128 FENTORA TABLET 100MCG 28 01/01/2022 164.90 1918.90 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459054228 FENTORA TABLET 200MCG 28 01/01/2022 208.30 2424.40 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459054428 FENTORA TABLET 400MCG 28 01/01/2022 302.30 3517.80 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459054628 FENTORA TABLET 600MCG 28 01/01/2022 392.40 4567.00 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459054828 FENTORA TABLET 800MCG 28 01/01/2022 483.40 5626.40 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 52544008001 FIORICET CAPSULE 50/300/40MG 100 01/01/2022 56.00 652.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 52544008201 FIORICET/CODEINE CAPSULE 50/300/40/30MG 100 01/01/2022 117.30 1365.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 00093360882 FLUTIC/SALMET INH PWD 113/14MCG 60 DOSE 02/07/2022 21.60 117.00 04/06/2035 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 00093360982 FLUTIC/SALMET INH PWD 232/14MCG 60 DOSE 02/07/2022 21.60 117.00 04/06/2035 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 00093360782 FLUTICA/SALMET INH PWD 55-14MCG 60 DOSE 02/07/2022 21.60 117.00 04/06/2035 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459041230 GABITRIL TABLET 12MG 30 01/01/2022 39.70 461.90 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459040230 GABITRIL TABLET 2MG 30 01/01/2022 30.70 357.30 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459040430 GABITRIL TABLET 4MG 30 01/01/2022 30.70 357.30 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459041630 GABITRIL TABLET16MG 30 01/01/2022 52.00 604.80 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844021552 GALZIN CAPSULE 25MG 250 01/01/2022 40.70 474.10 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 57844020852 GALZIN CAPSULE 50MG 250 01/01/2022 67.90 790.10 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 16252053901 ISRADIPINE 2.5MG CAPSULES 100 01/17/2022 47.40 144.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 16252054001 ISRADIPINE 5MG CAPSULES 100 01/17/2022 69.29 211.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459021530 NUVIGIL TABLET 150MG 30 01/01/2022 87.10 1013.50 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459022030 NUVIGIL TABLET 200MG 30 01/01/2022 87.10 1013.50 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459022530 NUVIGIL TABLET 250MG 30 01/01/2022 87.10 1013.50 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459020530 NUVIGIL TABLET 50MG 30 01/01/2022 28.90 336.80 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 00575620030 PROGLYCEM ORAL SUSPENSION 50MG/ML 30ML/ 1 BOTTLE 01/01/2022 32.40 376.80 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459010130 PROVIGIL TABLET 100MG 30 01/01/2022 121.90 1418.30 05/29/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459020130 PROVIGIL TABLET 200MG 30 01/01/2022 184.10 2142.90 05/29/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459017714 SYNRIBO INJECTION 3.5 MG 01/01/2022 104.50 1216.50 10/26/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2022 63459060106 TRISENOX VIAL 2 MG/ML 6 ML 01/01/2022 916.30 10663.80 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2022 59310081206 AIRDUO 113-14MCG 60 ACT /inhaler 01/01/2022 32.97 383.30 04/06/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2022 59310082206 AIRDUO 232-14MCG 60 ACT/ inhaler 01/01/2022 32.97 383.30 04/06/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2022 59310080506 AIRDUO 55-14MCG 60 ACT /inhaler 01/01/2022 32.97 383.30 04/06/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2022 59310040606 QNASL PLV INHALER 40MCG 60/ACT TRADE /1 inhaler 01/01/2022 24.21 281.73 10/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2022 59310041012 QNASL PLV INHALER 80MCG 120/ACT TRADE/ 1 inhaler 01/01/2022 24.21 281.73 10/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285042410 AYGESTIN TABLET 5MG 50 01/01/2022 26.10 303.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285012870 LOESTRIN FE TABLET 28 1.5MG/30MCG 140 01/01/2022 72.40 842.10 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285012570 LOESTRIN FE TABLET 28 1MG/20MCG 140 01/01/2022 72.40 842.10 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285013197 LOESTRIN TABLET 21 1.0MG/20MCG 105 01/01/2022 72.40 842.10 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285012797 LOESTRIN TABLET 21 1.5MG/30MCG 105 01/01/2022 72.40 842.10 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285009287 LOSEASONIQUE TABLET 0.1-0.02 & 0.01 MG 182 01/01/2022 84.10 979.20 12/05/2028 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285012058 MIRCETTE TABLET 28 .15MG/.02MG .01MG 01/01/2022 90.70 1055.10 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285006390 PREFEST TABLET 1/1-0.09 MG 180 01/01/2022 92.30 1074.70 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285043187 QUARTETTE TABLET 42-21-21-7 DAYS 182 01/01/2022 100.80 1172.70 03/11/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285008787 SEASONIQUE TABLET 0.15-0.03 &0.01 MG 182 01/01/2022 84.10 979.20 12/05/2028 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285036801 TREXALL TABLET 10MG 30 01/01/2022 90.80 1056.90 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285036901 TREXALL TABLET 15MG 30 01/01/2022 136.20 1585.40 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285036601 TREXALL TABLET 5MG 30 01/01/2022 45.40 528.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285036701 TREXALL TABLET 7.5MG 30 01/01/2022 68.10 792.70 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285004001 ZIAC TABLET 10MG/6.25MG 30 01/01/2022 21.20 247.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285004702 ZIAC TABLET 2.5MG/6.25MG 100 01/01/2022 70.70 823.20 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2022 51285005002 ZIAC TABLET 5MG/6.25MG 100 01/01/2022 70.70 823.20 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000134 Therakos, Inc. 03/31/2022 64067021601 UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML 01/01/2022 576.00 6974.00 None Single Source Drug None 1 This price is not reflective of discounts available to customers. This increase is the result of increased costs and other financial commitments of the company, including the recent launch of a new biologic therapy to treat adults with deep partial-thickness burns and the potential launch of another therapy later this year. Mallinckrodt continues to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. None This price is not reflective of discounts available to customers. This increase is the result of increased costs and other financial commitments of the company, including the recent launch of a new biologic therapy to treat adults with deep partial-thickness burns and the potential launch of another therapy later this year. Mallinckrodt continues to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. None None None None None None None None None None None This price information is reflective of the case unit of sale of the product. Uvadex is used only for extracorporeal photopheresis (ECP) therapy and is administered by a healthcare professional in a clinical setting.
Rx0000057 Theratechnologies Inc. 03/31/2022 62064024130 EGRIFTA SV 2MG LYO PWD 30/PAC 01/01/2022 367.00 6491.00 05/01/2023 Single Source Drug 0 1 None 1 None 1 None None None None None None None None None None Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000057 Theratechnologies Inc. 03/31/2022 62064012202 TROGARZO 150MG/ML 1.33ML SDV 2/PAC 01/01/2022 127.00 2676.00 04/01/2030 Single Source Drug 0 1 None 1 None 1 None None None None None None None None None None Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000183 Tris Pharma, Inc 03/31/2022 27808010201 Dyanavel XR 2.5mg/mL Suspension 464mL Bottle 01/03/2022 38.54 1341.99 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None